CLINICAL TRIALS PROFILE FOR CC-220
✉ Email this page to a colleague
Clinical Trials for CC-220
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01733875 ↗ | 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects | Completed | Celgene | Phase 1 | To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects |
NCT01733875 ↗ | 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects | Completed | Celgene Corporation | Phase 1 | To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects |
NCT02034773 ↗ | 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule | Completed | Celgene Corporation | Phase 1 | To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule |
NCT02185040 ↗ | A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. | Completed | Celgene | Phase 2 | The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus. |
NCT02185040 ↗ | A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. | Completed | Celgene Corporation | Phase 2 | The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus. |
NCT02192489 ↗ | A Phase 2 Study With CC-220 in Skin Sarcoidosis | Withdrawn | Celgene | Phase 2 | This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CC-220
Condition Name
Clinical Trial Locations for CC-220
Trials by Country
Clinical Trial Progress for CC-220
Clinical Trial Phase
Clinical Trial Sponsors for CC-220
Sponsor Name